7 Stocks in Spotlight, Experts Reveal New Buy Targets & Growth Outlooks

For investors navigating today's volatile market, staying aligned with institutional research is critical. Several premier foreign brokerage firms have just released fresh coverage reports on major Indian companies, outlining clear "Buy" recommendations and strategic "Hold" or "Underperform" cautions. Here is a breakdown of the key stock movements that could shape your portfolio today.

The EMS Sector: HSBC Bullish on Syrma SGS

HSBC has initiated coverage on Syrma SGS with a definitive 'Buy' rating and a target price of ₹1,750. Analysts highlight the company’s evolution from simple assembly to integrated product design. While they note that backward integration and new acquisitions are major growth levers, they also warn investors to monitor potential project execution delays and heightened competition in the electronics manufacturing space.

Retail Momentum: JPMorgan Stays 'Overweight' on Phoenix Mills

Phoenix Mills continues to impress major institutions. JPMorgan has maintained its 'Overweight' rating with a target price of ₹2,000. The optimism is rooted in robust mall performance, with customer spending surging 32% year-on-year in the first quarter. Despite some concerns regarding gold price fluctuations impacting jewellery sales, analysts believe the company's earnings remain well-shielded.

Banking & Finance: Jefferies Targets ₹1,700 for Axis Bank

Jefferies remains highly bullish on Axis Bank, recommending a 'Buy' with a target price of ₹1,700. The brokerage points to strong loan and deposit growth fueled by healthy corporate and SME demand. The report highlights an improving asset quality trend, which, coupled with a solid retail business, is expected to protect the bank's net interest margins and overall profitability.

Pharma Sector: Divergent Views on Growth

Jefferies has adopted a cautious stance on some pharma giants, assigning an 'Underperform' rating to Dr. Reddy’s Laboratories (Target: ₹1,040) and Cipla (Target: ₹1,120), citing limited immediate upside. In contrast, the firm remains bullish on Mankind Pharma, issuing a 'Buy' with a target price of ₹3,000. Analysts believe Mankind is in a recovery phase with limited downside risks, making it a preferred domestic play in the current market environment.

Infrastructure & Telecom: Holding Steady

• JSW Infrastructure: HSBC has assigned a 'Hold' rating with a target of ₹290. While a recent QIP has bolstered the company’s balance sheet, investors are advised to watch for timely project execution, which remains a key variable for reaching FY28 EBITDA targets.

• Indus Towers: Nomura is maintaining its 'Buy' conviction with a target of ₹505. Despite recent market corrections, the brokerage argues the sell-off was overdone. They suggest that the cost and operational difficulty of losing major tenancies remain low, potentially offering a strong entry point if current valuation levels hold.

Strategic Note for Investors

While brokerage reports provide vital insights into institutional thinking, they should serve as a guide rather than an absolute mandate. When considering stocks rated as 'Hold' or 'Underperform', retail investors should conduct their own due diligence, specifically looking at quarterly results, future debt levels, and long-term business strategy. Positive reports can certainly boost market confidence, but your investment decisions should always align with your personal risk appetite and financial goals.